Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study

Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is an ultra‐rare, blood‐clotting disorder. Management historically relies on plasma exchange and immunosuppression; however, a 10%–20% mortality rate is still observed. Caplacizumab binds to von Willebrand factor and directly inhibits platel...

Descripción completa

Detalles Bibliográficos
Autores principales: Scully, Marie, Dutt, Tina, Lester, Will, Farrington, Emily, Lockwood, Stevie, Perry, Richard, Holmes, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Sickle Cell, Thrombosis, and Benign Haematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422011/
https://www.ncbi.nlm.nih.gov/pubmed/36051029
http://dx.doi.org/10.1002/jha2.435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422011/
https://www.ncbi.nlm.nih.gov/pubmed/36051029
http://dx.doi.org/10.1002/jha2.435

Ejemplares similares